ImmuPharma (LON:IMM) Trading Up 27.3% - Time to Buy?

Key Points

• ImmuPharma's share price rose by 27.3% during trading, reaching as high as GBX 12.75 before settling at GBX 12.60.
• The company reported negative earnings per share (EPS) of GBX (0.38) and has a forecast of -339.00 EPS for the current fiscal year.
• ImmuPharma is a biopharmaceutical company focused on peptide-based therapeutics, with its lead program targeting the treatment of Lupus.

ImmuPharma plc (LON:IMM - Get Free Report)'s share price traded up 27.3% during trading on Friday . The stock traded as high as GBX 12.75 ($0.17) and last traded at GBX 12.60 ($0.17). 4,543,810 shares changed hands during trading, a decline of 46% from the average session volume of 8,432,391 shares. The stock had previously closed at GBX 9.90 ($0.13).

ImmuPharma Stock Up 27.3%

The company has a market cap of £63.34 million, a PE ratio of -1,415.73 and a beta of 1.53. The business has a 50-day simple moving average of GBX 7.92 and a 200-day simple moving average of GBX 4.36.

ImmuPharma (LON:IMM - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, research analysts forecast that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

ImmuPharma Company Profile

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.